Compositions and methods of treating pulmonary hypertension

Abstract

Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

What is claimed is: 
     
         1 - 32 . (canceled) 
     
     
         33 . A composition comprising ambrisentan and tadalafil, wherein the weight ratio of the ambrisentan to the tadalafil is about 1:2 or about 1:3. 
     
     
         34 . The composition of claim  1 , wherein the weight ratio of the ambrisentan to the tadalafil is about 1:2. 
     
     
         35 . The composition of claim  1 , wherein the ambrisentan to the tadalafil are co-formulated. 
     
     
         36 . The composition of claim  1 , which is formulated for parenteral administration. 
     
     
         37 . The composition of claim  1 , which is formulated for oral administration. 
     
     
         38 . The composition of  claim 37 , which is in a tablet form or capsule form. 
     
     
         39 . The composition of claim  1 , wherein the amount of ambrisentan is from about 1 mg to about 100 mg. 
     
     
         40 . The composition of claim  1 , wherein the amount of ambrisentan is from about 2 mg to about 20 mg. 
     
     
         41 . The composition of claim  1 , wherein the amount of tadalafil is from about 5 mg to about 500 mg. 
     
     
         42 . The composition of claim  1 , wherein the amount of tadalafil is from about 10 mg to about 100 mg. 
     
     
         43 . The composition of claim  1 , further comprising a drug selected from the group consisting of prostanoids, PDE5 inhibitors other than tadalafil, endothelin receptor antagonists other than ambrisentan, calcium channel blockers, diuretics, anticoagulants, oxygen and combinations thereof. 
     
     
         44 . A tablet or capsule comprising ambrisentan and tadalafil, wherein the weight ratio of the ambrisentan to the tadalafil is about 1:2. 
     
     
         45 . The tablet or capsule of  claim 44 , comprising about 5 mg ambrisentan and about 10 mg tadalafil. 
     
     
         46 . The tablet or capsule of  claim 44 , comprising about 10 mg ambrisentan and about 20 mg tadalafil. 
     
     
         47 . The tablet or capsule of  claim 44 , wherein the ambrisentan and the tadalafil are co-crystallized. 
     
     
         48 . The tablet or capsule of  claim 44 , further comprising a drug selected from the group consisting of prostanoids, PDE5 inhibitors other than tadalafil, endothelin receptor antagonists other than ambrisentan, calcium channel blockers, diuretics, anticoagulants, oxygen and combinations thereof.